Investors Target BioMimetic Over Bone Graft Statements

Law360, New York (August 15, 2011, 3:17 PM EDT) -- BioMimetic Therapeutics Inc. shareholders sued the biotechnology company Friday in Tennessee federal court, accusing its executives of puffing up the results of clinical trials for its star product, a synthetic bone graft.

BioMimetic's lead product candidate is Augment, a synthetic bone graft for use in foot and ankle fusion surgery. Although the company and its executives touted the new bone graft in regulatory filings and press releases, they knew that there were serious problems with it that the U.S. Food and Drug Administration ultimately revealed, according...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Duvall v. Lynch et al


Case Number

3:11-cv-00775

Court

Tennessee Middle

Nature of Suit

Stockholders Suits

Judge

Kevin H. Sharp

Date Filed

August 12, 2011

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.